BioSpace News Archive

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Natera, Inc., a global leader in cell-free DNA and genetic testing, announced the launch of a new cfDNA-based fetal RhD test.

Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024.

Precision BioSciences, Inc. announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B during a poster presentation at the European Association for Study of the Liver Congress 2024 being held June 5-8, 2024 in Milan, Italy.

Summit Therapeutics Inc. reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Tessellate BIO announces the appointment of Professor Sandra Strauss, University College London, to its Scientific Advisory Board.

Ventegra, Inc. announced the successful implementation of the Ventegra Specialty Inclusion program to maintain broad access for payors, providers, and members to beneficial medications at an affordable cost.

G1 Therapeutics, Inc., a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement for lerociclib for all indications except for certain radioprotectant uses.

LivaNova PLC, a market-leading medical technology company, reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024.